US6861422B2
(en)
|
2003-02-26 |
2005-03-01 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
|
DE102004029784A1
(en)
*
|
2004-06-21 |
2006-01-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Novel 2-Benzylaminodihydropteridinones, process for their preparation and their use as medicaments
|
DE102004033670A1
(en)
|
2004-07-09 |
2006-02-02 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
New pyridodihydropyrazinone, process for its preparation and its use as a medicament
|
US20060035903A1
(en)
|
2004-08-14 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Storage stable perfusion solution for dihydropteridinones
|
US7728134B2
(en)
|
2004-08-14 |
2010-06-01 |
Boehringer Ingelheim International Gmbh |
Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
|
US7759485B2
(en)
*
|
2004-08-14 |
2010-07-20 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of dihydropteridinones
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
US20060074088A1
(en)
|
2004-08-14 |
2006-04-06 |
Boehringer Ingelheim International Gmbh |
Dihydropteridinones for the treatment of cancer diseases
|
EP1630163A1
(en)
|
2004-08-25 |
2006-03-01 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Dihydropteridinones, methods for their preparation and their use as drugs
|
EP1632493A1
(en)
|
2004-08-25 |
2006-03-08 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Dihydropteridine derivatives, methods for their preparation and their use as drugs
|
JP2008510771A
(en)
*
|
2004-08-27 |
2008-04-10 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Dihydropteridinone, process for its preparation and its use as a pharmaceutical agent
|
DE602005023333D1
(en)
|
2004-10-15 |
2010-10-14 |
Takeda Pharmaceutical |
KINASE INHIBITORS
|
DE102004058337A1
(en)
|
2004-12-02 |
2006-06-14 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Process for the preparation of fused piperazin-2-one derivatives
|
US8119655B2
(en)
|
2005-10-07 |
2012-02-21 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
EP2340837B1
(en)
|
2005-11-11 |
2017-03-15 |
Boehringer Ingelheim International GmbH |
Combination treatment of cancer comprising egfr/her2 inhibitors
|
AU2012256410B2
(en)
*
|
2006-02-08 |
2016-04-28 |
Boehringer Ingelheim International Gmbh |
Trihydrochloride forms of a dihydropteridinone derivative and processes for preparation
|
US7439358B2
(en)
*
|
2006-02-08 |
2008-10-21 |
Boehringer Ingelheim International Gmbh |
Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
|
RU2475488C2
(en)
|
2006-02-14 |
2013-02-20 |
Вертекс Фармасьютикалз Инкорпорейтед |
Dihydrodiazepines useful as inhibitors of protein kinase
|
CN101448830A
(en)
*
|
2006-05-19 |
2009-06-03 |
阿斯利康(瑞典)有限公司 |
Dihydropteridine compounds as anti proliferative agents
|
TW200808325A
(en)
|
2006-07-06 |
2008-02-16 |
Astrazeneca Ab |
Novel compounds
|
US20100120717A1
(en)
|
2006-10-09 |
2010-05-13 |
Brown Jason W |
Kinase inhibitors
|
WO2008044041A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
EP2073807A1
(en)
|
2006-10-12 |
2009-07-01 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
KR20140104060A
(en)
|
2006-10-19 |
2014-08-27 |
시그날 파마소티칼 엘엘씨 |
Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
|
ES2359467T3
(en)
|
2006-12-14 |
2011-05-23 |
Vertex Pharmceuticals Incorporated |
USEFUL COMPOUNDS AS PROTEIN QUINASAS INHIBITORS.
|
EP2124951B1
(en)
|
2006-12-21 |
2014-05-21 |
Vertex Pharmaceuticals Inc. |
5-cyan0-4- (pyrrolo[2, 3b]pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
|
EP1953163A1
(en)
|
2007-02-01 |
2008-08-06 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Pteridinone derivatives as PI3-kinases inhibitors
|
EP2185559A1
(en)
*
|
2007-08-03 |
2010-05-19 |
Boehringer Ingelheim International GmbH |
Crystalline form of a dihydropteridione derivative
|
CN101878216B
(en)
|
2007-09-28 |
2013-07-10 |
西克拉塞尔有限公司 |
Pyrimidine derivatives as protein kinase inhibitors
|
US20090291938A1
(en)
*
|
2007-11-19 |
2009-11-26 |
Takeda Pharmaceutical Company Limited |
Polo-like kinase inhibitors
|
US8598172B2
(en)
|
2007-12-04 |
2013-12-03 |
Nerviano Medical Sciences S.R.L. |
Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
|
EP2100894A1
(en)
|
2008-03-12 |
2009-09-16 |
4Sc Ag |
Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
|
EP2112152A1
(en)
|
2008-04-22 |
2009-10-28 |
GPC Biotech AG |
Dihydropteridinones as Plk Inhibitors
|
GB0807452D0
(en)
*
|
2008-04-24 |
2008-05-28 |
Chroma Therapeutics Ltd |
PLK inhibitors
|
MX2011000021A
(en)
*
|
2008-06-23 |
2011-02-24 |
Vertex Pharma |
Protein kinase inhibitors.
|
WO2010021750A2
(en)
|
2008-08-21 |
2010-02-25 |
The Johns Hopkins University |
Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer
|
US20100075973A1
(en)
*
|
2008-08-28 |
2010-03-25 |
Takeda Pharmaceutical Company Limited |
Polo-like kinase inhibitors
|
US8110578B2
(en)
|
2008-10-27 |
2012-02-07 |
Signal Pharmaceuticals, Llc |
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
|
PT2364314E
(en)
|
2008-12-09 |
2014-06-09 |
Gilead Sciences Inc |
Modulators of toll-like receptors
|
JP5908728B2
(en)
*
|
2009-01-06 |
2016-04-26 |
ダナ ファーバー キャンサー インスティテュート インコーポレイテッド |
Pyrimido-diazepinone kinase skeletal compounds and methods of treating diseases
|
NZ619259A
(en)
|
2009-06-17 |
2015-07-31 |
Vertex Pharma |
Inhibitors of influenza viruses replication
|
ES2661850T3
(en)
|
2009-09-14 |
2018-04-04 |
Gilead Sciences, Inc. |
Toll type receiver modulators
|
CN102020643A
(en)
*
|
2009-09-22 |
2011-04-20 |
上海恒瑞医药有限公司 |
dihydropteridine ketone derivative, and preparation method and medicinal application thereof
|
AU2010298190A1
(en)
|
2009-09-25 |
2012-05-03 |
Vertex Pharmaceuticals Incorporated |
Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
|
KR20120094920A
(en)
|
2009-09-25 |
2012-08-27 |
버텍스 파마슈티칼스 인코포레이티드 |
Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
|
EP2493472B1
(en)
|
2009-10-26 |
2016-12-07 |
Signal Pharmaceuticals, LLC |
Methods of synthesis and purification of heteroaryl compounds
|
EP2325185A1
(en)
|
2009-10-28 |
2011-05-25 |
GPC Biotech AG |
Plk inhibitor
|
WO2011079118A1
(en)
*
|
2009-12-23 |
2011-06-30 |
Elan Pharmaceuticals, Inc |
Pteridinones as inhibitors of polo-like kinase
|
US20120329803A1
(en)
*
|
2010-02-17 |
2012-12-27 |
Boehringer Ingelheim International Gmbh |
Dihydropteridinones, method for production and use thereof
|
CN102190669A
(en)
*
|
2010-03-19 |
2011-09-21 |
江苏恒瑞医药股份有限公司 |
Dihydro pteridinone derivatives, preparation method thereof and application thereof in medicines
|
US8609672B2
(en)
|
2010-08-27 |
2013-12-17 |
University Of The Pacific |
Piperazinylpyrimidine analogues as protein kinase inhibitors
|
US8546566B2
(en)
*
|
2010-10-12 |
2013-10-01 |
Boehringer Ingelheim International Gmbh |
Process for manufacturing dihydropteridinones and intermediates thereof
|
US9358233B2
(en)
|
2010-11-29 |
2016-06-07 |
Boehringer Ingelheim International Gmbh |
Method for treating acute myeloid leukemia
|
JP2013545816A
(en)
|
2010-12-16 |
2013-12-26 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Influenza virus replication inhibitor
|
US20130131069A1
(en)
|
2011-05-13 |
2013-05-23 |
Boehringer Ingelheim International Gmbh |
Method for treatment of solid malignancies including advanced or metastatic solid malignancies
|
US9370535B2
(en)
|
2011-05-17 |
2016-06-21 |
Boehringer Ingelheim International Gmbh |
Method for treatment of advanced solid tumors
|
UA118010C2
(en)
|
2011-08-01 |
2018-11-12 |
Вертекс Фармасьютікалз Інкорпорейтед |
INFLUENCES OF INFLUENZA VIRUS REPLICATION
|
CN107157990B
(en)
|
2011-10-19 |
2020-01-07 |
西格诺药品有限公司 |
Treatment of cancer with TOR kinase inhibitors
|
EP2776444A4
(en)
|
2011-11-10 |
2015-07-22 |
Osi Pharmaceuticals Llc |
Dihydropteridinones
|
AU2012304276B2
(en)
|
2011-12-02 |
2015-01-15 |
Signal Pharmaceuticals, Llc |
Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one, a solid form thereof and methods of their use
|
JP5807750B2
(en)
*
|
2012-01-05 |
2015-11-10 |
トヨタ自動車株式会社 |
Fastening device and fastening method
|
US8865716B2
(en)
|
2012-02-23 |
2014-10-21 |
Boehringer Ingelheim International Gmbh |
Dihydropteridinones II
|
US9006226B2
(en)
|
2012-02-23 |
2015-04-14 |
Boehringer Ingelheim International Gmbh |
Dihydropteridinones I
|
BR112014020786A2
(en)
|
2012-02-24 |
2020-10-27 |
Signal Pharmaceuticals, Llc |
method for the treatment of lung cancer, method for achieving a response evaluation criterion in solid tumors, method for increasing survival
|
AU2013203714B2
(en)
|
2012-10-18 |
2015-12-03 |
Signal Pharmaceuticals, Llc |
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
|
US20140154304A1
(en)
|
2012-11-30 |
2014-06-05 |
Boehringer Ingelheim International Gmbh |
Combination therapy with volasertib
|
SG11201505446WA
(en)
|
2013-01-16 |
2015-08-28 |
Signal Pharm Llc |
Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
|
JP6072308B2
(en)
*
|
2013-02-21 |
2017-02-01 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Dihydropteridinone II
|
WO2014127815A1
(en)
*
|
2013-02-21 |
2014-08-28 |
Boehringer Ingelheim International Gmbh |
Dihydropteridinones i
|
EA030726B1
(en)
|
2013-04-17 |
2018-09-28 |
СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
PHARMACEUTICAL FORMULATIONS, PROCESSES, SOLID FORMS AND METHODS OF USE RELATING TO 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL)PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO[2,3-b]PYRAZIN-2(1H)-ONE
|
WO2014172430A1
(en)
|
2013-04-17 |
2014-10-23 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
|
TWI674897B
(en)
|
2013-04-17 |
2019-10-21 |
美商標誌製藥公司 |
Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
|
BR112015026297B1
(en)
|
2013-04-17 |
2022-08-23 |
Signal Pharmaceuticals, Llc |
USE OF A TOR KINASE INHIBITOR AND 5-SUBSTITUTED QUINAZOLINONE, PHARMACEUTICAL COMPOSITION THAT COMPRISES THEM, AND KIT
|
MX2015014599A
(en)
|
2013-04-17 |
2016-03-03 |
Signal Pharm Llc |
Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer.
|
SG10201801965RA
(en)
|
2013-04-17 |
2018-04-27 |
Signal Pharm Llc |
Treatment of cancer with dihydropyrazino-pyrazines
|
CA2908830C
(en)
|
2013-04-17 |
2021-12-07 |
Signal Pharmaceuticals, Llc |
Treatment of cancer with dihydropyrazino-pyrazines
|
CN105407892B
(en)
|
2013-05-29 |
2019-05-07 |
西格诺药品有限公司 |
A kind of pharmaceutical composition of compound, its solid form and their application method
|
JP2016525532A
(en)
|
2013-07-26 |
2016-08-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Treatment of myelodysplastic syndrome
|
ME03460B
(en)
|
2013-11-13 |
2020-01-20 |
Vertex Pharma |
Inhibitors of influenza viruses replication
|
BR112016010576B1
(en)
|
2013-11-13 |
2022-05-24 |
Vertex Pharmaceuticals Incorporated |
METHODS OF PREPARATION OF INFLUENZA VIRUS REPLICATION INHIBITORS
|
US20160347750A1
(en)
*
|
2014-01-31 |
2016-12-01 |
Dana-Farber Cancer Institute, Inc. |
Dihydropteridinone derivatives and uses thereof
|
JP2017504651A
(en)
|
2014-01-31 |
2017-02-09 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
Use of diazepan derivatives
|
US9718824B2
(en)
|
2014-04-16 |
2017-08-01 |
Signal Pharmaceuticals, Llc |
Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
|
US9512129B2
(en)
|
2014-04-16 |
2016-12-06 |
Signal Pharmaceuticals, Llc |
Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
|
NZ714742A
(en)
|
2014-04-16 |
2017-04-28 |
Signal Pharm Llc |
Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
|
US9737535B2
(en)
|
2014-04-16 |
2017-08-22 |
Signal Pharmaceuticals, Llc |
Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
|
CN104003989B
(en)
|
2014-05-26 |
2015-11-11 |
苏州明锐医药科技有限公司 |
Fu Lasai for and the preparation method of intermediate
|
CN106714800B
(en)
|
2014-07-11 |
2021-09-03 |
吉利德科学公司 |
TOLL-like receptor modulators for the treatment of HIV
|
NZ629796A
(en)
|
2014-07-14 |
2015-12-24 |
Signal Pharm Llc |
Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
|
KR20170024120A
(en)
|
2014-07-14 |
2017-03-06 |
시그날 파마소티칼 엘엘씨 |
Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
|
JP2017525759A
(en)
*
|
2014-08-08 |
2017-09-07 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
Dihydropteridinone derivatives and uses thereof
|
EP3177626A4
(en)
|
2014-08-08 |
2017-12-27 |
Dana Farber Cancer Institute, Inc. |
Diazepane derivatives and uses thereof
|
MX2017003288A
(en)
|
2014-09-16 |
2017-06-28 |
Gilead Sciences Inc |
Methods of preparing toll-like receptor modulators.
|
BR102015023450A2
(en)
|
2014-09-16 |
2016-04-12 |
Gilead Sciences Inc |
solid forms of a toll-like receptor modulator
|
US9867831B2
(en)
|
2014-10-01 |
2018-01-16 |
Boehringer Ingelheim International Gmbh |
Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
|
MA42422A
(en)
|
2015-05-13 |
2018-05-23 |
Vertex Pharma |
INHIBITORS OF INFLUENZA VIRUS REPLICATION
|
JP6704416B2
(en)
|
2015-05-13 |
2020-06-03 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Methods for preparing inhibitors of influenza virus replication
|
EP3307728A4
(en)
|
2015-06-12 |
2019-07-17 |
Dana Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
WO2017044792A1
(en)
|
2015-09-11 |
2017-03-16 |
Dana-Farber Cancer Institute, Inc. |
Acetamide thienotriazoldiazepines and uses thereof
|
WO2017044849A1
(en)
|
2015-09-11 |
2017-03-16 |
Dana-Farber Cancer Institute, Inc. |
Cyano thienotriazolodiazepines and uses thereof
|
US10751306B2
(en)
|
2015-11-06 |
2020-08-25 |
The Johns Hopkins University |
Methods of treating liver fibrosis by administering 3-bromopyruvate
|
SG11201803210YA
(en)
|
2015-11-25 |
2018-05-30 |
Dana Farber Cancer Inst Inc |
Bivalent bromodomain inhibitors and uses thereof
|
CN105801582A
(en)
*
|
2016-04-12 |
2016-07-27 |
合肥工业大学 |
Novel dihydro pteridinone derivative, preparing method thereof and application to medicine
|
DE102017005091A1
(en)
|
2016-05-30 |
2017-11-30 |
Bayer Pharma Aktiengesellschaft |
Substituted 3,4-dihydropyrido [2,3-b] pyrazine-2 (1H) -one
|
DE102017005089A1
(en)
|
2016-05-30 |
2017-11-30 |
Bayer Pharma Aktiengesellschaft |
Substituted 3,4-dihydroquinoxaline-2 (1H) -one
|
CN106977584B
(en)
*
|
2017-04-19 |
2019-12-06 |
吉林大学 |
Compound for targeted ubiquitination degradation of PLK1 and BRD4 proteins and application thereof
|
CA3067585A1
(en)
|
2017-06-22 |
2018-12-27 |
Celgene Corporation |
Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
|
AU2018392805A1
(en)
*
|
2017-12-22 |
2020-05-07 |
Dana-Farber Cancer Institute, Inc. |
NEK inhibitors and methods of use
|
WO2019145410A1
(en)
|
2018-01-25 |
2019-08-01 |
Boehringer Ingelheim International Gmbh |
Combination treatment of acute myeloid leukemia
|
CA3121202A1
(en)
|
2018-11-30 |
2020-06-04 |
Nuvation Bio Inc. |
Pyrrole and pyrazole compounds and methods of use thereof
|
CN110343109B
(en)
*
|
2019-08-21 |
2021-11-23 |
郑州大学 |
Dihydropyridone-sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method and application thereof
|
WO2023196943A1
(en)
|
2022-04-08 |
2023-10-12 |
Inhibrx, Inc. |
Dr5 agonist and plk1 inhibitor or cdk inhibitor combination therapy
|